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showed 100% similarity with B. spiel-
manii. B. garinii was detected in the 
heart of 2 animals (from Berlin and 
Karlsruhe);  B. afzelii in 3 animals 
(in the kidney of 2 from Hamburg 
and Karlsruhe and in the bladder of 1 
from Rhineland-Palatinate). A single 
animal (from Karlsruhe) had B. afzelii 
in the kidney and bladder and B. ga-
rinii in the heart. Preliminary results 
have also shown that ticks collected 
from hedgehogs from the Karlsruhe 
site were infected with B. afzelii (an 
I. hexagonus nymph and an I. ricinus 
female) and with B. spielmanii (an I. 
ricinus female, a nymph, and a larva) 
(Skuballa et al., unpub. data).
These results show, that hedge-
hogs harbor at least 3 of the 5 rec-
ognized  Borrelia genospecies found 
in Germany, all of which are known 
(B. afzelii, B. garinii) or are strongly 
suspected (B. spielmanii) of being 
pathogens for humans (9,10). To our 
knowledge, ours is the ﬁ  rst report of 
B. spielmanii from hedgehogs, a Bor-
relia sp. that is usually associated 
with rodents, especially with garden 
and hazel dormice (10). That Borrelia 
spp. infections commonly occur in 
European hedgehogs is likely. How-
ever, questions remain about the role 
of these pathogens in regulating the 
populations of European hedgehogs 
and about the status of these common 
synanthropic mammals as a reservoir 
host of B. burgdorferi s. l. in periurban 
and rural environments.
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Invasive 
Cryptococcosis and 
Adalimumab 
Treatment 
To the Editor: Tumor necrosis 
factor-α (TNF-α) antagonists are im-
munosuppressants that have shown ef-
ﬁ  cacy in treating inﬂ  ammatory disor-
ders. However, a recent meta-analysis 
of controlled trials has shown evidence 
of increased risk for serious infections 
in patients with rheumatoid arthritis 
treated with TNF-α antagonists (1).
Adalimumab is a human mono-
clonal antibody to TNF-α approved 
by the US Food and Drug Administra-
tion (FDA) for treatment of rheuma-
toid arthritis. The Spanish registry of 
adverse events of biologic therapies in 
rheumatic diseases reported that 1,080 
patients were treated with adalimumab 
from 2003 through 2006 and no cases 
of cryptococcosis were recorded (2). 
No cases of cryptococcosis have been 
detected in 10,050 treated patients in 
the US postmarketing database for 
adalimumab (3). We report invasive 
cryptococcosis in a patient receiving 
adalimumab. This case underscores 
the relationship between TNF antago-
nists and emergence of severe and dif-
ﬁ  cult-to-treat opportunistic infections.
A 69-year-old woman with rheu-
matoid arthritis diagnosed in 2002 
was referred to our hospital for se-
vere acute inﬂ  ammation of the second 
ﬁ  nger of the left hand. She had been 
treated with oral corticosteroids (pred-
nisone, 7.5 mg/day) and several dis-
ease-modifying antirheumatic drugs, 
including chloroquine, methotrexate, LETTERS
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and sulfasalazin, without improve-
ment. One year before the current 
episode, therapy with adalimumab, 40 
mg subcutaneously every 2 weeks for 
52 weeks, was started and she showed 
an acceptable clinical response. She 
had no recent trauma. 
Examination showed severe teno-
synovitis of the digital ﬂ  exor tendon 
with intense edema and compartmen-
tal signs (online Appendix Figure, 
available from www.cdc.gov/EID/
content/13/6/953-appG.htm). She had 
an axillary temperature of 36.7°C and 
an admission leukocyte count of 5,900 
cells/μL. Results of a neurologic ex-
amination and a chest radiograph were 
normal. Early surgical decompres-
sion was performed. Intraoperative 
ﬁ   ndings indicated extensive subcu-
taneous celullitis with inﬁ  ltration  of 
vasculonervous bundles and ﬂ  exor 
tendon synovitis. Culture of extracted 
material from 4 samples, including 
a biopsy specimen of subcutaneous 
tissue, identiﬁ  ed  Cryptococcus neo-
formans susceptible to amphotericin 
B, azoles, and ﬂ  ucytosine. Results of 
cerebrospinal ﬂ  uid analysis were nor-
mal. A cranial computed tomographic 
scan showed no focal lesions. Results 
of a serum cryptococcal latex test and 
HIV serologic analysis were negative. 
Magnetic resonance imaging of the 
ﬁ   nger showed inﬂ   ammation of soft 
tissues, including the ﬂ  exor  tendon, 
but no signs of arthritis or osteomyeli-
tis. Treatment with adalimumab was 
discontinued. 
Intravenous liposomal amphoteri-
cin B, 300 mg once a day, and intrave-
nous ﬂ  ucytosine, 2.5 g 3× a day, were 
administered for 7 days. Treatment 
with intravenous ﬂ  uconazole,  400 
mg twice a day for 21 days, was then 
started. Inﬂ  ammatory signs decreased. 
Because residual soft tissue necrosis 
was extensive, reconstructive surgery 
was not performed, and her second 
ﬁ  nger was amputated during the third 
week after admission. A pathologic 
examination showed chronic necrotiz-
ing granulomatous inﬂ  ammation with 
typical encapsulated fungal forms of 
Cryptococcus spp. inside multinucle-
ated giant cells. These forms were 
observed by staining specimens with 
hematoxylin and eosin and Mayer 
mucicarmine (Figure). After an un-
eventful postoperative period, the pa-
tient was discharged and received oral 
ﬂ  uconazole, 200 mg once a day for 6 
months. Two years later, the patient 
remains asymptomatic and receives 
therapy with methotrexate, salazo-
pyrin, and prednisone.
The rate of serious infections in 
the US clinical trial safety database 
of adalimumab as of April 2005 was 
5.1/100 patient-years. This rate is 
similar to that reported in the general 
population with rheumatoid arthritis. 
However, as in our case, some infec-
tions associated with adalimumab are 
severe and difﬁ  cult to treat (3). Cryp-
tococcosis has not been previously 
associated with use of adalimumab. 
Cryptococcal infections have been de-
scribed in 19 patients receiving TNF-
α antagonists other than adalimumab 
(inﬂ  iximab or etanercept) in the FDA 
Adverse Event Reporting System 
from 1998 to 2002 (4). Three cases of 
cryptococcosis in patients receiving 
TNF-α antagonists have been reported 
(5–7). 
The association between crypto-
coccosis and use of TFN-α antagonists 
can be explained by the immune re-
sponse to C. neoformans, which relies 
on effective T-cell host defenses and 
in which TNF-α has an essential role. 
TFN-α is involved in maintaining a 
T-helper cell type 1 immune response 
because it induces production of inter-
leukin-12 (IL-12) and IL-18, with sub-
sequent production of fungicidal inter-
feron-γ (8). In animal models, TNF-α 
blockers are associated with reduced 
recruitment of inﬂ  ammatory cells to 
the area of infection and an increased 
risk for cryptococcal dissemination 
(9). Moreover, C. neoformans impairs 
production of TNF-α, IL-1β, and IL-6 
and increases levels of IL-10, which 
induce a T-helper cell type 2 immune 
response (10). Cryptococcal virulence 
factors impart greater dependence 
upon TNF-α for a sufﬁ  cient host re-
sponse (9). Adalimumab may increase 
immunosuppression, which is required 
for a  cryptococcal infection.
Our patient received a low dose 
of prednisone. Although corticoste-
roids are a risk factor for cutaneous 
cryptococcosis, cases with serious 
outcomes rarely occur. However, the 
Figure. Histiocytic granuloma with lymphocytes and multinucleated giant cells and an 
encapsulated intracytoplasmic mucicarmine-positive structure identiﬁ  ed as a Cryptococcus 
sp. (arrow) (hematoxylin and eosin– and Mayer mucicarmine–stained, magniﬁ  cation 
×400). LETTERS
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risk for fungal infection related to low 
doses of steroids is minimal. Active 
surveillance, as well as analysis of 
associated risk factors, is required to 
detect concurrence of severe oppor-
tunistic infections in patients treated 
with TNF antagonists and to identify 
patients who could beneﬁ  t from these 
therapies with fewer risks.
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Determining Risk 
Factors for 
Infection with 
Inﬂ  uenza A (H5N1)
To the Editor: Novel antigenic 
subtypes of inﬂ   uenza viruses have 
been introduced periodically into the 
human population, resulting in large-
scale global outbreaks (1). Highly 
pathogenic avian inﬂ  uenza  (H5N1) 
viruses reemerged in 2003. Since 
then, they have reached endemic lev-
els among poultry in several South-
east Asian countries, and across Asia, 
they have caused nearly 300 human 
infections, with a high rate of mortal-
ity (1,2). The results of many studies, 
including those for one recently con-
ducted by Dinh et al. (3), have been 
published in an effort to identify the 
source(s) and modes of transmission 
of inﬂ  uenza A (H5N1) to humans and 
to guide the control and prevention of 
inﬂ  uenza infection.
Although new data regarding 
inﬂ  uenza A (H5N1) are urgently re-
quired, scientiﬁ  c rigor must be main-
tained during research and analysis 
to prevent misidentiﬁ  cation of expo-
sures as a risk factor for the disease 
and to prevent creation of iatrogenic 
panic among the exposed popula-
tion and the scientiﬁ  c community (4). 
One point of scientiﬁ  c rigor that must 
be maintained is the use of adequate 
statistical analysis. The multivariate 
model in the study by Dinh et al. (3) 
was constructed by using a backward, 
stepwise variable selection strategy, in 
which variables with p<0.20 were in-
cluded in the initial model. However, 
such a strategy has resulted in a ﬁ  rst 
model and subsequent steps with far 
more than 10 variables per outcome 
(e.g., 28 persons with avian ﬂ  u), re-
sulting in model overﬁ   tting (i.e., a 
statistical model that is too complex 
for the amount of data), which could 
result in imprecise estimates or spuri-
ous associations (5).
We believe that scientiﬁ  c methods 
must be meticulously applied when 
planning, executing, analyzing, and 
interpreting the results of inﬂ  uenza 
(H5N1) studies to prevent identiﬁ  ca-
tion of false risk factors for acquiring 
infection.
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